On the other hand, loss or alteration of membrane CD26 expression has been described in melanoma, NSCLC, prostate and endometrial adenocarcinoma, and ovarian and breast carcinoma [185,190,191,192,193,194,195,196,197]. This evidence concerns the gene DPP4 and endometrium adenocarcinoma.